Edgar Filing: Holmes Scott A - Form 4

Holmes Scott A Form 4		
June 27, 2012		
FORM 4 UNITED ST	CATES SECURITIES AND EXCHA Washington, D.C. 20549	Number: 3235-0287
if no longer subject to Section 16. Form 4 or Form 5 subject to Form 5 Filed pursu	NT OF CHANGES IN BENEFICIA SECURITIES ant to Section 16(a) of the Securities E of the Public Utility Holding Compan 30(h) of the Investment Company Ac	Estimated average burden hours per response 0.5 Exchange Act of 1934, y Act of 1935 or Section
(Print or Type Responses)		
1. Name and Address of Reporting Per Holmes Scott A	 2. Issuer Name and Ticker or Tradi Symbol AMAG PHARMACEUTICAI INC. [AMAG] 	Issuer
(Last) (First) (Mid C/O AMAG PHARMACEUTICALS, INC., HAYDEN AVENUE	(Month/Day/Year) 06/25/2012	Director 10% Owner Officer (give title Other (specify below) below) below) Chief Accounting Officer
(Street) LEXINGTON, MA 02421	4. If Amendment, Date Original Filed(Month/Day/Year)	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person
(City) (State) (Zi	p) Table I - Non-Derivative Secu	rities Acquired, Disposed of, or Beneficially Owned
(Instr. 3) an	A. Deemed 3. 4. Securities kecution Date, if ty Code Disposed of (D) Anoth/Day/Year) (Instr. 8) (Instr. 3, 4 and 4) (A) or	5. Amount of r6. Ownership Form: Direct7. Nature of Indirect)Beneficially(D) or IndirectBeneficial
Reminder: Report on a separate line fo	r each class of securities beneficially owned di	

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Holmes Scott A - Form 4

1. Title of Derivative Security (Instr. 3)		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactie Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day.	ate	7. Title and A Underlying S (Instr. 3 and	Securities	8 E S (1
				Code V	(A) (D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Options	\$ 14.89	06/25/2012		А	30,000	(1)	06/25/2019	Common Stock	30,000	

Reporting Owners

Reporting Owner Name / Address			Relationships	
	Director	10% Owner	Officer	Other
Holmes Scott A C/O AMAG PHARMACEUTICALS, 100 HAYDEN AVENUE LEXINGTON, MA 02421	INC.		Chief Accounting Officer	
Signatures				
Nancy R. Smith, attorney-in-fact	06/27/2012			

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. 25% of
(1) this option will vest and become exercisable on June 25, 2013, the first anniversary of the grant, and thereafter the remainder will vest and become exercisable in equal 6.25% quarterly installments through June 25, 2016.

(2) Price is not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.